For years, Moderna, Inc (NASDAQ: MRNA)'s biggest challenge wasn't developing new medicines — it was convincing investors that it could thrive after COVID-19. The company's vaccine transformed it into one of the world's most recognizable biotech names, but as the pandemic demand faded, so did its revenue and stock price.

Now, a breakthrough in cancer treatment may finally give Moderna the second act investors have been waiting for.

COVID Turned Moderna Into a Biotech Powerhouse, Then Came the Hard Part

Revenue climbed to nearly $19 billion in 2021 and $20 billion in 2022 from just about $800 million in 2020, in the wake of its COVID-19 vaccine, turning the once little-known biotech into one of the industry's biggest success stories. Once the COVID-19 hype died down, revenue again stalled back to about $7 billion in 2023 and is being reported lower each year. In 2025, Moderna fell short of breaching $2 billion in annual revenue.

This drop left investors questioning whether the company could build another meaningful business beyond the COVID-19 vaccine. While the company continued investing billions of dollars across vaccines and therapeutics, Wall Street largely viewed it as a business searching for a successor to its pandemic blockbuster.

The Cancer Breakthrough Changes the Conversation

That narrative shifted this week.

Moderna and Merck & Co Inc. (NYSE: MRK) announced that their personalized mRNA cancer vaccine met the primary endpoints in a Phase 3 melanoma trial, marking the first mRNA-based cancer treatment to demonstrate success in a Phase 3 trial. The treatment is designed by analyzing a patient's tumor and creating a customized vaccine that helps the immune system recognize and attack remaining cancer cells after surgery.

More importantly for investors, the melanoma result is about more than one drug. It provides Moderna with its strongest clinical evidence yet that its mRNA platform could have applications beyond infectious diseases. The company is already studying the same personalized approach in other cancers, including lung, bladder and kidney, giving investors a glimpse of a much larger opportunity if the technology continues to deliver.

Investment Takeaway

The market's reaction wasn't simply a celebration of a promising melanoma treatment. It reflected a broader shift in how investors may begin to value Moderna. For the first time since the pandemic boom faded, the company has a compelling answer to the question that has defined its investment story: what comes next?

The Phase 3 success does not guarantee commercial success, and investors will still want to see detailed trial data and progress in other cancers. But if this breakthrough proves to be the first validation of a broader oncology platform, COVID-19 may be remembered as the chapter that made Moderna famous — while cancer becomes the one that defines its future.